Otsuka F, Morita K, Takeuchi M, Yamauchi T, Ogura T, Sekines K, Miura M, Hirakawa M, Makino H
Department of Medicine III, Okayama University Medical School, Japan.
Anesth Analg. 1999 Jan;88(1):181-7. doi: 10.1097/00000539-199901000-00034.
A radioimmunoassay has been established to measure urinary aquaporin-2 excretion (u-AQP2). To elucidate how u-AQP2 changes when endogenous vasopressin is increased independently of plasma osmolality, we estimated u-AQP2 during general anesthesia for surgery. We collected urine and blood samples from 50 patients before and 90 and 180 min after anesthetic induction. Plasma (29.1+/-12.6 pg/mL) and urinary (565.1+/-207.0 ng/gCr) vasopressin levels were markedly increased after anesthetic induction. Although no significant alteration of plasma osmolality or serum sodium concentration was observed during 180 min, u-AQP2 was significantly increased (preinduction 224.5+/-24.2 fmol/ mgCr; 90 min 243.3+/-31.8; 180 min 331.4+/-45.9), paralleling an increase of plasma and urinary vasopressin. The plasma vasopressin concentration after anesthetic induction was far in excess of that expected based on plasma osmolality. Individual plasma and urinary vasopressin concentrations correlated significantly with u-AQP2. At 180 min after anesthesia, plasma osmolality did not change, but urine osmolality decreased despite increased u-AQP2, and a preanesthetic positive correlation between urine osmolality and u-AQP2 disappeared. Thus, although u-AQP2 correlates with increased intrinsic vasopressin levels, the increase in u-AQP2 did not directly contribute to urine concentration. Apparently, an escape from the physiologic effects of high vasopressin level occurs during anesthesia via a mechanism independent of aquaporin-2. We conclude that the anesthetic would interfere with the urinary concentrating capacity at the level of AQP2-action.
The excessive increase of intrinsic vasopressin exactly augmented urinary aquaporin-2 excretion, resulting in urine concentration; however, anesthesia seemed to modify this process possibly by interfering with the aquaporin-2 action.
已建立一种放射免疫分析法来测量尿水通道蛋白-2排泄量(u-AQP2)。为了阐明当内源性血管加压素独立于血浆渗透压增加时u-AQP2如何变化,我们在手术全身麻醉期间估计了u-AQP2。我们在麻醉诱导前以及诱导后90分钟和180分钟从50例患者中采集尿液和血液样本。麻醉诱导后血浆(29.1±12.6 pg/mL)和尿液(565.1±207.0 ng/gCr)血管加压素水平显著升高。尽管在180分钟内未观察到血浆渗透压或血清钠浓度有显著变化,但u-AQP2显著增加(诱导前224.5±24.2 fmol/mgCr;90分钟243.3±31.8;180分钟331.4±45.9),与血浆和尿液血管加压素的增加平行。麻醉诱导后血浆血管加压素浓度远远超过基于血浆渗透压预期的浓度。个体血浆和尿液血管加压素浓度与u-AQP2显著相关。麻醉后180分钟时,血浆渗透压未改变,但尽管u-AQP2增加,尿渗透压却降低,并且麻醉前尿渗透压与u-AQP2之间的正相关消失。因此,尽管u-AQP2与内源性血管加压素水平升高相关,但u-AQP2的增加并未直接导致尿液浓缩。显然,在麻醉期间通过一种独立于水通道蛋白-2的机制发生了对高血管加压素水平生理作用的逃避。我们得出结论,麻醉会在水通道蛋白-2作用水平干扰尿液浓缩能力。
内源性血管加压素的过度增加确实增加了尿水通道蛋白-2排泄,导致尿液浓缩;然而,麻醉似乎通过干扰水通道蛋白-2的作用来改变这一过程。